VolitionRx Partners with Werfen to Advance Diagnostic Testing for Antiphospholipid Syndrome
VolitionRx has signed an agreement with Werfen to evaluate its Nu.Q NETs assay for improved detection and monitoring of antiphospholipid syndrome, potentially transforming diagnosis and management for millions of patients worldwide.
VolitionRx Ltd. (NYSE American: VNRX) has entered into a Research License and Exclusive Commercial Option Rights Agreement with Werfen's Immunoassay Technology Center to assess antiphospholipid syndrome using Volition's proprietary Nu.Q H3.1 Neutrophil Extracellular Traps assay on Werfen platforms. This collaboration represents a significant step forward in the diagnostic testing landscape for autoimmune disorders.
Gael Forterre, Chief Commercial Officer at Volition, stated that the agreement aligns with the company's strategy to license its Nu.Q NETs test to large worldwide companies, leveraging their disease-specific knowledge, product development capabilities, regulatory experience, and installed base of proprietary analyzers. The partnership aims to capitalize on Werfen's extensive expertise in specialized diagnostics to accelerate the validation and potential commercialization of the innovative test.
Marta Palicio, Werfen's Immunoassay Technology Center Innovation R&D Director, confirmed that the Nu.Q NETs assay has already been successfully transferred to Werfen's ACL AcuStar platform. Early results in detecting NETs levels in APS patients have shown promise, prompting further validation and a comprehensive clinical utility study. The research will determine the marker's potential role as a thrombosis risk indicator in APS patients, potentially enabling better management of this complex syndrome through more precise diagnostic tools available at https://ibn.fm/DXJnL.
Antiphospholipid syndrome affects approximately 4 million people worldwide and is typically diagnosed through two positive antibody tests conducted at least 12 weeks apart. Volition believes its Nu.Q NETs test represents the first CE-IVD biomarker under investigation for APS, offering the potential to significantly improve both diagnostic decision-making and ongoing patient monitoring. The collaboration could expand Werfen's portfolio in APS testing while providing Volition with access to Werfen's global distribution network and regulatory expertise.
The partnership underscores the growing importance of epigenetic testing in autoimmune disease management and reflects the increasing trend of diagnostic companies collaborating to combine innovative biomarker technology with established platform capabilities. Successful validation of the Nu.Q NETs assay could lead to earlier detection and more effective monitoring of APS, ultimately improving patient outcomes and quality of life for millions affected by this challenging autoimmune disorder.